Article metrics

Download PDFPDF

451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2021

AbstractFullPdf
Nov 2020223025
Dec 20203607
Jan 20213406
Feb 20211602
Mar 20213004
Apr 20214804
May 2021001
Jun 2021007
Jul 2021008
Aug 2021006
Sep 2021007
Total387077